Hospital was Haemonetics’s largest product and service line in fiscal 2026, bringing in $588.30M of $1.33B (44%).
| Product and Service | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma | $569.54M | $535.43M | $524.46M | ||||||||||||
| Hospital | $456.29M | $564.27M | $588.30M | ||||||||||||
| Plasma Products & Services | — | — | — | ||||||||||||
| Blood Center Products & Services | — | — | — | ||||||||||||
| Blood Center Disposables | — | — | — | ||||||||||||
| Plasma Disposables | — | — | — | ||||||||||||
| Blood Center | $283.23M | $261.12M | $221.27M | ||||||||||||
| Hospital Products & Services | — | — | — | ||||||||||||
| Whole Blood | — | — | — | ||||||||||||
| Platelet | — | — | — | ||||||||||||
| Cell Processing | — | — | — | ||||||||||||
| Surgical | — | — | — | ||||||||||||
| Software Solutions | — | — | — | ||||||||||||
| Equipment & Other | — | — | — | ||||||||||||
| Hemostasis Management | — | — | — | ||||||||||||
| Red Cell | — | — | — | ||||||||||||
| Orthopat | — | — | — | ||||||||||||
| Diagnostics | — | — | — | ||||||||||||
| Total | $1.31B | $1.36B | $1.33B |
Haemonetics brought in $1.33B from its three product and service lines in fiscal 2026, the year ended March 28, 2026. That was down 2.0% from $1.36B in fiscal 2025. Hospital was the largest at $588.30M (44.1%), ahead of Plasma at $524.46M (39.3%) and Blood Center at $221.27M (16.6%).
Compared with fiscal 2025, Hospital grew fastest, up 4.3% to $588.30M, while Blood Center fell the most, down 15.3% to $221.27M. From fiscal 2024 to 2026, combined revenue from these lines grew from $1.31B to $1.33B, a compound annual growth rate of 0.9%. Hospital's share of the total rose from 34.9% to 44.1%.
United States was Haemonetics’s largest region in fiscal 2026, bringing in $982.18M of $1.33B (74%).
| Geography | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $842.90M | $970.01M | $1.01B | $982.18M | |||||||||
| Europe | $156.68M | $160.14M | $175.66M | $185.02M | |||||||||
| Rest Of Asia | $104.14M | $107.54M | $92.31M | $87.21M | |||||||||
| Asia | — | — | — | — | |||||||||
| Japan | $61.30M | $58.09M | $62.41M | $68.20M | |||||||||
| Plasma | — | — | — | — | |||||||||
| Other | $3.65M | $13.28M | $19.54M | $11.42M | |||||||||
| Other Country Or Region | — | — | — | — | |||||||||
| All Other | — | — | — | — | |||||||||
| Total | $1.17B | $1.31B | $1.36B | $1.33B |
Haemonetics brought in $1.33B from its five regions in fiscal 2026, the year ended March 28, 2026. That was down 2.0% from $1.36B in fiscal 2025. United States was the largest at $982.18M (73.6%), ahead of Europe at $185.02M (13.9%) and Rest Of Asia at $87.21M (6.5%). The other two regions brought in $79.62M combined.
Compared with fiscal 2025, Japan grew fastest, up 9.3% to $68.20M, while Rest Of Asia fell the most, down 5.5% to $87.21M. From fiscal 2023 to 2026, combined revenue from these regions grew from $1.17B to $1.33B, a compound annual growth rate of 4.5%. United States' share of the total rose from 72.1% to 73.6%.
Plasma was Haemonetics’s largest segment in fiscal 2026, bringing in $524.46M of $1.33B (39%).
| Segment | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|
| Plasma | $499.92M | $569.54M | $535.43M | $524.46M |
| Blood Management Technologies | $254.99M | $282.00M | $309.25M | $354.30M |
| Apheresis | $207.62M | $211.17M | $213.13M | $220.86M |
| Interventional Technologies | $126.72M | $174.29M | $255.02M | $234.01M |
| Whole Blood | $79.42M | $72.06M | $47.99M | $406.00K |
| Total | $1.17B | $1.31B | $1.36B | $1.33B |
Haemonetics brought in $1.33B from its five segments in fiscal 2026, the year ended March 28, 2026. That was down 2.0% from $1.36B in fiscal 2025. Plasma was the largest at $524.46M (39.3%), ahead of Blood Management Technologies at $354.30M (26.6%) and Interventional Technologies at $234.01M (17.5%). The other two segments brought in $221.27M combined.
Compared with fiscal 2025, Blood Management Technologies grew fastest, up 14.6% to $354.30M, while Interventional Technologies fell the most, down 8.2% to $234.01M. From fiscal 2023 to 2026, combined revenue from these segments grew from $1.17B to $1.33B, a compound annual growth rate of 4.5%. Plasma's share of the total fell from 42.8% to 39.3%.
Haemonetics (HAE) reports its revenue by product and service, by geography and by segment. In fiscal 2026, Hospital was its largest product and service line, bringing in $588.30M (44.1% of the total), followed by Plasma at $524.46M (39.3%).
Hospital was Haemonetics' largest product and service line in fiscal 2026, bringing in $588.30M, or 44.1% of the $1.33B total across its three product and service lines.
United States was Haemonetics' largest region in fiscal 2026, bringing in $982.18M, or 73.6% of the $1.33B total across its five regions.
Plasma was Haemonetics' largest segment in fiscal 2026, bringing in $524.46M, or 39.3% of the $1.33B total across its five segments.
Among Haemonetics' product and service lines that make up at least 2% of revenue, Hospital grew fastest in fiscal 2026, up 4.3% from $564.27M to $588.30M.
Every figure comes from Haemonetics' annual financial filings, as reported. Each line keeps the name Haemonetics gives it, and years follow its fiscal calendar.
Haemonetics' revenue by product and service goes back to fiscal 2010, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.